ArticleDisease markers2020
Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation.
Article in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Circulating Growth Differentiation Factor 15 (GDF15) in Paediatric Disease: A Systematic Review.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Associations of Growth Differentiation Factor 15 in Chronic Kidney Disease.Kidney international reports · 2026Article
- GDF-15 and uEGF Independently Associate With CKD Progression in Children.Kidney international reports · 2025Article
- GDF15, EGF, and Neopterin in Assessing Progression of Pediatric Chronic Kidney Disease Using Artificial Intelligence Tools-A Pilot Study.International journal of molecular sciences · 2025Article
- Molecular and Functional Significance of Growth Differentiation Factor-15: A Review on Cardiovascular-Kidney-Metabolic Biomarker.Current cardiology reviews · 2025Review
- GDF15 Interference Regulates Proliferation, Inflammation, and Autophagy of Lipopolysaccharide-induced Mesangial Cells by Inhibiting PI3K/ AKT/mTOR Signaling.Endocrine, metabolic & immune disorders drug targets · 2024Article
- Role and Mechanism of Growth Differentiation Factor 15 in Chronic Kidney Disease.Journal of inflammation research · 2024Review
- GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease.Italian journal of pediatrics · 2023Article
- Stress-responsive Gdf15 counteracts renointestinal toxicity via autophagic and microbiota reprogramming.Communications biology · 2023Article
- Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction.ESC heart failure · 2023Article
- Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD.Kidney360 · 2022Article
- Aptamers Targeting Cardiac Biomarkers as an Analytical Tool for the Diagnostics of Cardiovascular Diseases: A Review.Biomedicines · 2022Review
- Urinary Growth Differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease.Journal of nephrology · 2021Article
- Growth Differentiation Factor 15: A Biomarker with High Clinical Potential in the Evaluation of Kidney Transplant Candidates.Journal of clinical medicine · 2020Article
- Reply to the Letter to the Editor: "GDF-15 - A matter of the heart or the kidney?"International journal of cardiology · 2020Article
- Prognostic Value of Growth Differentiation Factor 15 in Kidney Donors and Recipients.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth differentiation factor 15 (GDF-15) is strongly associated with cardiovascular disease (CVD). The aim of our study was to evaluate plasma and urinary levels of GDF-15 after pediatric renal transplantation (Rtx) and in children with chronic kidney disease (CKD) and its associations to cardiovascular risk factors. In this cross-sectional study, GDF-15 was measured in plasma and urine from 53 children with a renal transplant and 83 children with CKD and related to cardiovascular risk factors (hypertension, obesity, and cholesterol) and kidney function. Forty healthy children served as a control group. Plasma levels of GDF-15 (median and range) for a Tx (transplantation) cohort, CKD cohort, and healthy controls were, respectively, 865 ng/L (463-3039 ng/L), 508 ng/L (183-3279 ng/L), and 390 ng/L (306-657 ng/L). The CKD and Tx cohorts both had significantly higher GDF-15 levels than the control group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.